The Mounjaro BMI Requirement: Facts, Thresholds and What Else Counts

The myth: if your BMI hits 30, you're automatically approved

A lot of people arrive at this question assuming the BMI number alone opens a door. It doesn't, and being clear about that upfront saves a lot of frustration. The licensed BMI threshold of 30 (or 27 with a qualifying condition) is the floor, not the answer. A prescriber still assesses whether Mounjaro is clinically appropriate for you as an individual. Certain medical histories, medicines and conditions mean treatment may not be right regardless of where your BMI sits. Pancreatitis history, some thyroid conditions and specific drug interactions are among the factors a prescriber will want to know about. None of that is intended to be discouraging, it's the clinical process working as it should. You can use the NHS BMI calculator to confirm your own figure before starting a consultation, which saves time. If you want a clear breakdown of exactly what BMI is required for Mounjaro and how the thresholds are applied in practice, that's worth reading before your consultation. The BMI number matters; it's just not the finish line.

What the private licence actually requires (and where the NHS sets a different bar

The Mounjaro SmPC) the legally binding prescribing document, licenses tirzepatide for adults with a BMI of 30 or above, or 27 or above when at least one weight-related condition is present. Qualifying conditions include type 2 diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea and cardiovascular disease. That is the private-prescription eligibility framework, and it's the one that applies when you go through a regulated online pharmacy rather than waiting for an NHS prescription. The NHS threshold is higher. NICE's appraisal of tirzepatide (TA1026), published in December 2024, recommends it for NHS use in adults with a BMI of 35 or above who have at least one weight-related comorbidity, and access is being phased in gradually by cohort. If you are considering the cost side of private treatment alongside these thresholds, our Mounjaro cost guide covers what legitimate private pricing typically includes. The distinction between private and NHS eligibility trips people up regularly; they are genuinely different frameworks operating under the same medicine.

How ethnic background adjusts the threshold, and why it matters

UK clinical guidance acknowledges that standard BMI cut-offs can underestimate health risk in certain populations. For adults from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the relevant thresholds under UK guidance are typically 2.5 kg/m² lower, so 27.5 instead of 30, or 24.5 instead of 27, as the relevant qualifying points. NICE's TA1026 recommendation builds this adjustment in explicitly, and NHS England's guidance on weight management injections reflects it too. In practice, whether and how this applies to a specific individual is a clinical judgement made by the prescriber during assessment. Our page on BMI for Mounjaro explains how these adjusted cut-offs work across different population groups and what they mean for eligibility. The adjustment exists because BMI was developed on European population data and has real limitations as a universal tool.

What a clinical assessment looks at beyond the number on the scale

If you've done the maths and your BMI clears the threshold, the next question is what else a prescriber considers. Honestly, this is the part most online searches don't cover well, and it's the part that most affects real-world outcomes. A prescriber will look at your qualifying conditions and whether any are already managed with medicines that could interact with tirzepatide. They'll ask about your history with eating disorders, gastrointestinal conditions and any previous weight-loss treatments. For a fuller picture of all the clinical requirements, our prescribing requirements page covers these in detail, including the HbA1c requirements for Mounjaro that apply if you have type 2 diabetes. Pregnancy, breastfeeding and plans to conceive are also relevant, Mounjaro is not recommended in these circumstances, and women using oral contraceptives are advised to add a non-oral method for the first four weeks of treatment and after each dose increase, as the absorption of the pill may be reduced. At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not an automated system. There is no instant approval; there is same-day review. If you want to understand more about how the full eligibility picture comes together, our detailed requirements guide walks through each factor. When you're ready, speaking to our prescribers is the clearest way to find out whether Mounjaro is suitable for you.